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Jung et al., 2002; Rock, 1996; Rock et al., 1990a; Shen
et al., 1997; Watts, 1997). In this process, exogenous
antigens are internalized into endocytic compartments
(Kovacsovics-Bankowski et al., 1993; Norbury et al.,
1995; Pfeifer et al., 1993) and then can be presented on
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MHC class I molecules by at least two distinct pathways.2 Fox Chase Cancer Center
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phagosomes into the cytosol (Kovacsovics-Bankowski3 Department of Pathology
et al., 1993; Norbury et al., 1995; Rodriguez et al., 1999).Harvard Medical School
The antigens are degraded by proteasomes into oligo-Boston, Massachusetts 02115
peptides that are then transported by the transporter
associated with antigen processing (TAP) into the ER
(Kovacsovics-Bankowski and Rock, 1995) or back intoSummary
the phagosome (Ackerman et al., 2003; Guermonprez
et al., 2003; Houde et al., 2003). Antigenic peptides areThe immune system detects viral infections and muta-
then bound by MHC class I molecules and transportedtions in parenchymal cells when antigens from these
to the cell surface. Therefore, the phagosome-to-cytosolcells are crosspresented on MHC class I molecules of
pathway is inhibited by proteasome inhibitors and byprofessional antigen-presenting cells (APC). Exogenous
mutations that block TAP function.antigens are crosspresented through TAP-dependent
The other crosspresentation pathway(s) is less well(cytosolic) or poorly understood TAP-independent (vac-
understood. Peptides are presumed to be generateduolar) pathways. The TAP-independent pathway is
within endocytic compartments, and, accordingly, thisblocked by the cysteine protease inhibitor, leupeptin,
pathway is not affected by proteasome inhibitors (Songbut not by proteasome inhibitors, which is opposite
and Harding, 1996). However, the proteases that gener-to the effects of these agents on the TAP-dependent
ate the MHC class I-presented peptides are unknown.pathway. Dendritic cells lacking the cysteine protease
Moreover, whether this “vacuolar” pathway is depen-cathepsin S lack the TAP-independent pathway. Mice
dent on the TAP transporter is controversial (Chefalowhose APC lack cathepsin S have reduced crossprim-
et al., 2003). So far, this vacuolar pathway has beening to particulate and cell-associated antigens, as well
demonstrated clearly only in cell culture (Rock, 1996).as to influenza virus. Cathepsin S-deficient phago-
TAP-independent crosspresentation has been observedsomes generate a class I-presented peptide poorly.
in vivo (Norbury et al., 2001; Ruedl et al., 2002); however,In contrast, cathepsin S-sufficient phagosomes and
whether it occurs by the vacuolar pathway is unknown.recombinant cathepsin S produce the mature epitope.
Endocytic compartments contain many proteases
Therefore, cathepsin S plays a major role in generating
(Chapman et al., 1997; Villadangos et al., 1999) that de-
presented peptides for the vacuolar pathway of cross-
grade internalized proteins and play key roles in class II
presentation, and this mechanism is active in vivo. antigen presentation. The cysteine proteases, cathepsin
(Cat) B, L, and S, an asparagine-specific endopeptidase,
Introduction and the aspartyl proteases, Cat D and E, may participate
in the generation of MHC class II-presented peptides.
To generate CTL responses in vivo, naive T cells must However, in most cases the inhibition of any one prote-
first be stimulated with antigenic peptides presented ase does not block MHC class II presentation, presum-
on MHC class I molecules of antigen-presenting cells ably because lysosomal proteases are redundant (Naka-
(APC). If the APC is synthesizing antigens, e.g., from a gawa and Rudensky, 1999; Villadangos et al., 1999). In
viral infection, then it can directly process and present addition, Cat S in DC (Nakagawa et al., 1999; Shi et al.,
these antigens to T cells. However, to generate immune 1999), Cat L in thymic cortical epithelium (Nakagawa et
responses to antigens that are exclusively produced al., 1998) and probably Cat F in macrophages (Shi et
by nonprofessional APC, e.g., tumor, cellular, or tissue al., 2000) degrade the MHC class II-associated invariant
tropic viral proteins (Huang et al., 1994; Kurts et al., chain (Ii), a critical step for its removal from MHC class
1996; Li et al., 2001; Sigal et al., 1999), it is necessary II molecules. Whether these same endosomal proteases
for APC to acquire and present antigens from the extra- also play a role in the vacuolar crosspresentation path-
cellular environment, a process termed crosspresen- way is unknown; however, they may be different be-
tation. cause peptides presented on class I molecules are
shorter and of a precise length, while those on class IIMacrophages and dendritic cells (DC) are the principal
are longer and of variable length.cells that crosspresent exogenous antigens in vitro and
Given the important role of crosspriming in generatingin vivo (den Haan et al., 2000; Heath and Carbone, 2001;
CTL responses to virus, tumor, and transplants, it is
important to understand how these pathways operate*Correspondence: kenneth.rock@umassmed.edu
in vivo. Here we show that Cat S plays a key role in4 Present address: Department of Dermatology, The Brigham and
the TAP-independent crosspresentation pathway bothWomen’s Hospital, 77 Avenue Louis Pasteur, Boston, Massachu-
setts 02155. in vitro and in vivo.
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Figure 1. Particulate Antigens Can Be Cross-
presented by a TAP-Dependent Mechanism
and a TAP-Independent Pathway that Re-
quires Cysteine Proteases
(A) TAP-dependent and -independent pre-
sentation of particulate antigens by profes-
sional APC. WT C57BL/6 and TAP/ BM DC
(5  104) were incubated with the indicated
concentrations of iron oxide-OVA (left) or
PLGA-OVA (right) and with RF33.70 T-T hy-
bridoma (specific for Kb/SIINFEKL) (1  105)
for 16 hr. The content of IL-2 in supernatants
was measured using CTLL2 indicator cells.
(B) Effects of proteasome inhibitor and leu-
peptin on PLGA-OVA antigen presentation.
(a) A combination of proteasome and cys-
teine protease inhibitors blocks exogenous
antigen presentation on class I. WT BM DC
were preincubated with no inhibitors, 100
g/ml leupeptin, 2 M -lactone, or a combi-
nation of both inhibitors for 30 min. PLGA-
OVA was then added at a concentration of 5
g/ml for 5 hr in the continuous presence of
inhibitors, and the cells were then fixed. They
were then titrated and tested for their ability to stimulate RF33.70 hybridomas to produce IL-2. (b) Leupeptin inhibits exogenous antigen class
I presentation by TAP-deficient DC. Similar to (a), except BM DC from TAP/ mice were used instead of wild-type BM DC in the antigen
presentation assay in the presence of 2 M -lactone or 100 g/ml leupeptin. The results are expressed as the mean cpm [3H]thymidine
incorporation of cultures in duplicate, and variation between wells was 10%.
Results cysteine proteases contribute to the presentation of ex-
ogenous PLGA-OVA, but leupeptin-insensitive prote-
ases were also involved in this process. Since a portionTAP-Dependent and -Independent Crosspresentation
Why certain forms of antigens are crosspresented by of the response to PLGA-OVA was TAP dependent, we
tested the effect of treating DC with the highly specificthe phagosome-to-cytosol versus vacuolar pathway is
unknown. To study the vacuolar pathway, we searched proteasome inhibitor, clasto-lactacystin -lactone (re-
ferred to as -lactone below). This agent also partiallyfor a form of ovalbumin that was presented in a TAP-
independent manner. We empirically discovered that inhibited the presentation of PLGA-OVA (Figure 1Ba).
The concentration of -lactone used effective becauseOVA incorporated into microspheres of poly-lactide
poly-glycolide (PLGA), a biodegradable copolymer, was it completely inhibited the generation of SIINFEKL-Kb
complexes from OVA iron oxide beads and from vacciniapresented by TAP-deficient bone marrow (BM)-derived
DC to an OVA-specific T cell hybridoma. The responses OVA recombinants; both of these sources of antigen are
presented exclusively by the cytosolic pathway (Kovac-stimulated by the TAP-deficient DC were only slightly
decreased compared to C57BL/6 wild-type DC (Figure sovics-Bankowski and Rock, 1995; Rock et al., 1994).
In contrast, leupeptin had no effect on the presentation1A, right), which was in contrast to results with OVA iron
oxide or latex beads where TAP function was absolutely of these forms of antigen. Treatment with a combination
of leupeptin and -lactone almost completely inhibitedrequired (Figure 1A, left) (Kovacsovics-Bankowski and
Rock, 1995). These results indicate that PLGA-OVA can the crosspresentation of PLGA-OVA (Figure 1Ba). There-
fore, class I-presented peptides are generated frombe presented by a TAP-independent pathway. When the
concentration of antigen was more limiting and/or the PLGA-OVA by two separate proteolytic pathways, one
involving proteasomes and the other involving cys-incubation was shorter (e.g., APC fixed after 5 hr), the TAP-
deficient APC still presented the antigen, but less well teine protease(s).
Proteasomes generate the peptides presented by thethan wild-type cells (Figure 2B and data not shown). This
suggested that PLGA-OVA might be presented through TAP-dependent pathway of crosspresentation (Kovac-
sovics-Bankowski and Rock, 1995). To test whether cys-two distinct pathways, one TAP-dependent and one
TAP-independent. teine proteases generated the peptides presented by
the TAP-independent pathway, we treated TAP-defi-
cient DC with leupeptin. This agent almost completelyTwo Crosspresentation Pathways Use Different
Proteolytic Mechanisms abolished the TAP-independent presentation of PLGA-
OVA (Figure 1Bb). In contrast, the proteasome inhibitorWe used protease inhibitors to investigate the proteo-
lytic processes involved in the TAP-dependent and TAP- -lactone had no effect (Figure 1Bb). Therefore, cysteine
proteases are required for the TAP-independent path-independent crosspresentation pathways. In wild-type
DC, a broadly active cysteine protease inhibitor, leupep- way of presentation.
tin, partially inhibited the crosspresentation of PLGA-
OVA (Figure 1Ba). The concentration of leupeptin used Cathepsin S Plays a Critical Role
in Vacuolar Crosspresentationwas sufficient to inhibit cysteine proteases because it
completely blocked the presentation of OVA on MHC Cysteine proteases are found in the cytosol (e.g., cal-
pains) and in endocytic compartments (e.g., cathep-class II (data not shown). These results indicated that
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doses (data not shown). Therefore, Cat S plays a role
in crosspresentation, especially when antigen is limiting.
PLGA-OVA was still presented by Cat S-deficient DC,
albeit at a reduced level (Figure 2Ac). To determine
whether this Cat S-independent presentation was due
to other cysteine proteases or presentation by the pro-
teasome-TAP-dependent pathway, we analyzed WT,
TAP/, Cat S/, and TAP/Cat S/ DC. As in the
previous experiments, Cat S- and TAP-deficient DC
showed reduced crosspresentation of PLGA-OVA as
compared to the wild-type APC (Figure 2Ba). However,
the presentation by TAP and Cat S double-deficient DC
was almost completely abolished (Figure 2Ba). This re-
sult indicates that the residual presentation in Cat
S-deficient DC was due to the coexisting TAP-depen-
dent cytosolic pathway and not due to the participation
of other endosomal proteases. More importantly, it dem-
onstrates Cat S is a critical enzyme in TAP-independent
presentation on MHC class I and that the presented
peptides are indeed generated in endosomal compart-
ments.
To investigate whether the loss of Cat S led to any
unexpected impairment of the class I pathway, we ana-
lyzed the presentation of a SIINFEKL minigene targeted
into the ER by a signal sequence; this construct is pre-
sented efficiently by TAP/ cells. TAP/Cat S/ DC
infected with a vaccinia recombinant expressing the
minigene presented SIINFEKL as efficiently as did TAP-
deficient DC (Figure 2Bb), even under limiting condi-
tions. These results indicate that the loss of Cat S did
not impair synthesis, assembly, or transport of MHC
Figure 2. Cat S Is Required for the TAP-Independent Antigen Pre-
class I molecules.sentation on MHC Class I
Taken together, the experiments with inhibitors and
(A) Cat S, but not Cat L and B, is involved in exogenous antigen
Cat S  TAP-deficient cells complement one anotherpresentation on MHC class I. BM DC from Cat L/ (a), Cat B/ (b),
and indicate that there are two distinct and independentCat S/ (c) (solid squares) and C57BL/6 mice (open squares) were
incubated with 5 g/ml PLGA-OVA for 5 hr and then fixed. OVA crosspresentation pathways, cytosolic and vacuolar.
SIINFEKL presentation on Kb was determined as described in Figure For the vacuolar pathway, the cysteine protease Cat S
1. (d) Similar to (c), except, instead of PLGA-OVA, 10 g/ml of iron is an important protease, at least for the crosspresenta-
oxide bead OVA was used in antigen presentation assay. tion of PLGA-OVA.
(B) Cat S is required for TAP-independent antigen presentation on
MHC class I. (a) BM DC from C57BL/6 (open squares), Cat S/
(open diamonds), TAP/ (open circles), and TAP/Cat S/ (solid
squares) were compared for their ability to crosspresent PLGA-OVA Cat S Is Not Affecting Crosspresentation
antigen on class I Kb. The procedures were essentially identical to through Hydrolysis of Invariant Chain
that described in (A). (b) Similar to (a), except the DC were infected In most cells, newly synthesized MHC class I molecules
with rVacESOVA instead of being incubated with PLGA-OVA. are not transported into endosomes. However, in APC
the Ii chain binds to some class I molecules and directs
their transport into endocytic compartments (Sugita and
sins). Since the presentation of peptides generated by Brenner, 1995; Vigna et al., 1996). Therefore, it is possi-
the cysteine protease(s) is TAP independent, it was un- ble that similar to the MHC class II antigen presentation
likely that they were produced in the cytosol. We there- pathway, the Ii chain is needed to deliver class I mole-
fore examined the role of various cathepsins in this path- cules into the vacuolar pathway and that Cat S is then
way. Cat L-deficient (Figure 2Aa) and Cat B-deficient required to remove the Ii chain. However, Ii-deficient
(Figure 2Ab) DC both crosspresented PLGA-OVA equiv- DC crosspresented PLGA-OVA similarly to wild-type DC
alently to their wild-type counterparts. Therefore, Cat B (Figure 3). Therefore the Ii chain is not required for cross-
and L are dispensable for crosspresentation of PLGA-OVA. presentation by the vacuolar pathway. Moreover, Ii and
Cat S is a cysteine protease that is preferentially ex- Cat S double-deficient DC also had lower class I antigen
pressed in APC including DC, macrophages, and B cells. presentation than that of Ii (single)-deficient DC or wild-
Interestingly, the crosspresentation of PLGA-OVA was type DC (Figure 3). This indicated that Cat S was still
reduced in Cat S-deficient BM DC (Figure 2Ac). In con- required for crosspresentation in Ii-deficient APC. This
trast, the presentation of OVA bound to iron oxide beads latter result also ruled out the possibility that the reduc-
(BioMag OVA), which does not require cysteine prote- tion in antigen presentation in Cat S-deficient cells was
ases, was not affected by Cat S deficiency (Figure 2Ad). due to an accumulation of Ii chain in endosomes. There-
We also observed that antigen presentation by Cat S/ fore, Cat S must be needed in the vacuolar pathway for
something other than hydrolyzing the Ii chain.DC was even more markedly reduced at low antigen
Immunity
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Figure 3. Cat S Is Not Affecting Crosspresentation through Hydroly-
sis of Invariant Chain
BM DC from wild-type C57BL/6, Cat S/, Ii/, or Cat S/Ii/ were
incubated with 5 g/ml PLGA-OVA for 5 hr, fixed, and then titrated
at the indicated cell numbers in 96-well plates to which RF33.70
hybridoma cells were added (1 105/well). After 16 hr, supernatants
were harvested and IL-2 production was determined using CTLL2
cells. The results are expressed as mean cpm of triplicate wells.
The SD is less than 10%.
Cat S Generates the Correct Class
I-Presented Peptide
It has been presumed in the vacuolar pathway that the
class I-presented peptides were generated in phago-
somes, although this had not been formally shown.
Therefore, we tested whether isolated phagosomes
could produce SIINFEKL when incubated with OVA.
When peptides were generated from wild-type phago-
somes and pulsed onto fixed APC, they stimulated SIIN-
FEKL-specific OT-I T cells (Figure 4A). We next exam-
ined whether Cat S plays any role in this process. There
was a marked reduction in the production of the OVA-
presented peptide by phagosomes lacking Cat S (Figure
4A). Therefore, Cat S is necessary for the generation of Figure 4. Cat S Can Generate the Correct Peptide for Presentation
on MHC Class Ithis class I-presented peptide in phagosomes.
It was possible that in addition to Cat S, other phago- (A) Generation of an antigenic peptide by phagosomes requires Cat
S. Peptides generated from OVA incubated with phagosomes fromsomal proteases were needed to generate SIINFEKL.
BM DC of C57BL/6 and Cat S/ were pulsed onto DC2.4 cells andTherefore, we next investigated whether purified recom-
assayed for their ability to stimulate OT-1 T cells as described inbinant Cat S by itself could generate SIINFEKL from
the Experimental Procedures.
OVA. An OVA peptide that could stimulate SIINFEKL- (B) Generation of SIINFEKL by Cat S. OVA was digested with recom-
specific T cells was detected and shown to be SIINFEKL binant Cat S, and the resulting peptides were separated by reverse
phase HPLC. SIINFEKL was assayed as in (A). Under these condi-by HPLC (Figure 4B). Cat S produced SIINFEKL over a
tions, SIINFEKL elutes in fraction 25.wide range in pH including near neutral conditions (Fig-
(C) Cat S generates SIINFEKL over a wide range of pH. The peptidesure 4C). Therefore, Cat S is both necessary and sufficient
generated by Cat S at the indicated pH were pulsed onto fixed APCfor generating this class I-presented peptide.
and assayed as in (A).
Role of Cat S in Antigen Presentation In Vivo
To address the contribution of the cytosolic and vacuo- and subsequently the proliferation of the OVA-specific
T cells in lymphoid organs was analyzed by measuringlar pathways in generating CTL responses in vivo,
C57BL/6, TAP/, Cat S /, or TAP/Cat S/ mice their content of CFSE by flow cytometry.
Three days after injection, PLGA-OVA stimulated OT-Iwere injected with SIINFEKLKb-specific transgenic
T cells (OT-I) labeled with the fluorescent dye CFSE. T cells to proliferate in the draining lymph nodes of wild-
type mice in a dose-dependent manner (Figure 5 andSince there could be a defect in CD4 T cell help in Cat
S-deficient mice (Nakagawa et al., 1999; Shi et al., 1999), data not shown). In TAP/ or Cat S/ mice, PLGA-OVA
also stimulated OT-I T cells to proliferate but to a lesserand this could potentially reduce the priming of CTL,
CD4 T cells were depleted by injecting anti-CD4 (GK1.5) degree than in wild-type controls (Figure 5A). There was
also a marked reduction of OT-I T cells that had under-antibody in vivo. We verified by flow cytometry that
CD4 T cells had been eliminated from the treated gone proliferation in the spleen of Cat S-deficient mice
at a later time point, i.e., day 5 (data not shown). Four-mice and had previously shown that OVA particles can
prime CD8 T cells in the absence of CD4 T cells (Mint- fold higher amounts of PLGA OVA stimulated similar
amounts of proliferation in wild-type, TAP/, and Catern et al., 2002; Rock and Clark, 1996). The recipients
were then immunized with various doses of PLGA-OVA, S/ mice at day 5 (Figure 5B). These results suggest
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Figure 5. Proliferation of Adoptively Transferred OT-I T Cells upon PLGA-OVA Stimulation
CFSE-labeled OT-I T cells (4  106) were injected i.v. into the indicated mice. One day after transfer, the indicated amounts of PLGA-OVA (A
and B) were injected s.c. on the left flank. In another experiment, C57BL/6 BM DC were pulsed with 10 g/ml OVA SIINFEKL peptide and
washed, and 1  106 cells were injected s.c. in the left flank (C). At the indicated time points, draining inguinal LN were harvested, and LN
cells were stained with PerCP-CD8 and APC-Thy1.1, and analyzed by flow cytometry. CD8 and Thy1.1 double-positive T cells were analyzed
for proliferation (CFSE dilution) using FlowJo software.
that in vivo, TAP-dependent and Cat S-dependent Cat S Contributes to Crosspriming
to Cell-Associated Antigenmechanisms contribute to T cells responses, which is
similar to what was observed in vitro (Figures 1 and 2). Tumor and other cell-associated antigens are cross-
presented by professional APC in vivo at least in partWe next tested whether there was a further reduction
in the priming of OT-I T cells in TAP/Cat S/ recipient by the TAP-dependent pathway (den Haan et al., 2000;
Huang et al., 1996; Li et al., 2001; Liu et al., 2002). Tomice. PLGA-OVA stimulated little to no OT-I T cell prolif-
eration at day 3 (Figure 5A), even at high doses and later address the potential involvement of the vacuolar path-
way in this process, we adoptively transferred OT-I cellstime points (Figure 5B). In multiple experiments, only
7.2  10% OT-I T cells proliferated in Cat S and TAP- into WT, Cat S/, TAP/, or Cat S/TAP/ mice (H-2b)
and then immunized these animals with an allogeneicdeficient mice versus 91  8% in wild-type mice, a
reduction of 92%. These results mirror the in vitro (H-2K) cell line (DAP) stably transfected with OVA (Shen
and Rock, 2004). In this system the OT-I T cells can onlystudies (Figure 2Ba) and indicate that OVA is being pre-
sented by both TAP- and Cat S-dependent pathways be stimulated when the OVA made by the H-2k cell line
is crosspresented on host H-2b APC. OT-I proliferationin vivo. The small response to high doses of antigen in
the TAP and Cat S double-deficient mice may indicate was clearly detectable in TAP/ recipients, although at
lower levels than that of B6 WT (Figure 6). The T cellsthat some other protease(s) can generate SIINFEKL, but
were also stimulated to proliferate in Cat S/ mice.clearly this is a minor pathway.
However, they failed to proliferate in TAP/Cat S/To exclude the possibility that the loss of OT-I prolifer-
mice. Therefore, the Cat S-dependent vacuolar pathwayation in TAP/Cat S/ mice was due to some defect
is also involved in crosspresentation of cell-associatedother than crosspresentation (e.g., in T cell homing, sur-
antigen in vivo.vival, or other steps), we immunized these mice with
wild-type DC pulsed with SIINFEKL peptide. Equivalent
OT-I responses were observed in TAP/Cat S/, wild- Role of Cat S in Crosspriming to Viral Antigens
type, and single knockout mice on days 3–5 (Figure 5C We next investigated the role of Cat S in TAP-indepen-
and data not shown). Therefore, the lack of response to dent viral antigen presentation in vivo. Wild-type mice
PLGA-OVA in TAP/Cat S/ mice is due to a failure of were irradiated and reconstituted their hematopoietic
antigen presentation and not due to other defects in the systems with bone marrow from either WT, TAP/, Cat
S/, or TAP/Cat S/ deficient mice. Four monthshost environment.
Immunity
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Figure 6. Cell-Associated OVA Is Crosspresented Using Both the Cytosolic and Vacuolar Pathways
CFSE-labeled OT-I T cells (4  106) were i.v. injected into the indicated mice. One day after transfer, 5  106 OVA-transfected allogeneic (H-2k)
DAP cells were injected s.c. on the left flank. On day 5, draining inguinal LN were harvested, and LN cells were stained with PerCP-CD8 and APC-
Thy1.1 and analyzed by flow cytometry. CD8 and Thy1.1 double-positive T cells were analyzed for proliferation (FL-1) using FlowJo software.
after reconstitution, the chimeras were used for experi- nogen, these findings suggest that the ASNENMETM
CD8 T cells in these animals were fully competent toments. Since CD4 help is not required for CTL responses
to influenza (Belz et al., 2002), CD4 T cells were elimi- respond to this peptide, and the APC, although defective
in their ability to generate presented peptides by thenated from the chimeric mice with anti-CD4 antibody;
therefore, any impairment of CTL responses in these cytosolic and vacuolar pathways, were otherwise fully
functional.treated mice would not be due to an effect of Cat S on
CD4 T cell help. To exclude the possibility that the differences we ob-
served between groups were skewed by the in vitroWe studied the generation of CTL to the influenza
Db-restricted NP366-374 (ASNENMETM) epitope. When stimulation of T cells, we assayed the CTL activity in
influenza-infected chimeric mice during the primary im-B6→B6 chimeras were infected with a low dose (25
HAU) of influenza virus and their spleens stimulated with mune responses in vivo. One week after infection,
ASNENMETM-pulsed or unpulsed CFSE-labeled targetASNENMETM, CTL were readily detected in a 51Cr re-
lease assay (Figure 7A). Consistent with our previous cells were injected into mice, and the survival of the
labeled cells was evaluated by flow cytometry (Barberreport (Sigal and Rock, 2000), there was no detectable
CTL response in TAP/→ B6 or TAP/Cat S/→B6 et al., 2003). The killing of ASNENMETM-pulsed cells
was reduced in both Cat S- and TAP-deficient BM chi-chimeras (Figure 7A). In contrast, CTL were primed in
Cat S/→B6 chimeras (Figure 7A), although the magni- meras and was almost completely abolished in TAP and
Cat S double-deficient chimeras (Figure 7D). Therefore,tude of the response was reduced compared to B6→B6
chimeras. Therefore, the response to this dose of influ- these results confirm that Cat S is playing a role in the
generation of the primary CTL response to influenzaenza is largely TAP dependent, although there may be
a contribution from Cat S dependent mechanisms. virus in vivo.
To further determine the generality of our findings, weAs previously described (Sigal and Rock, 2000), higher
doses (100 HAU) of influenza elicited CTL responses in investigated whether Cat S was involved in the genera-
tion of CTL responses to a third unrelated epitope,B6→B6 chimeras (mean lytic unit [LU] 	 911) and re-
duced but detectable ones in TAP/→B6 chimeras SSLENFRAYV, a Db-restricted influenza peptide from the
acid polymerase protein (PA). The killing of SSLEN-(mean LU 	 37) (Figure 7B). The CTL response in Cat
S/→B6 chimeras was also lower than that of B6→B6 FRAYV-pulsed target cells in vivo was reduced in Cat
S- and TAP-deficient BM chimeras and further reducedchimeras (mean LU 	 280) (Figure 7B). Most important,
in TAP/Cat S/→B6 chimeras, CTL responses were in Cat S and TAP double-deficient animals (Figure 7E).
On the basis of these data, we conclude that Cat Smarkedly reduced to or slightly above background levels
(mean LU  1) (Figure 7B). Therefore, Cat S is also plays a major role in TAP-independent CTL response to
influenza viral antigens in vivo. Moreover, since Cat Splaying a role in the generation of CTL response to influ-
enza virus in vivo. plays a critical role in the vacuolar but not the endoge-
nous pathway of presentation, the Cat S-dependentAs a control, we immunized the chimeric animals with
a vaccinia virus containing a minigene encoding ASNEN- component of the CTL response to influenza virus must
be due to crosspresentation.METM with a signal sequence. The peptide expressed
from this construct is cotranslationally transported into
the ER and does not require TAP or vacuolar proteases Discussion
for presentation. Similar CTL responses (LU ranging
from 30 to 51) were generated in chimeric mice regard- The best-characterized mechanism of crosspresenta-
tion is the phagosome-to-cytosol pathway. In this path-less of whether they had Cat S/, TAP/, and Cat
S/TAP/ bone marrow (Figure 7C). Therefore, with way antigens internalized by macrophages and DC are
transferred from endocytic compartments into the cyto-the caveat that the minigene construct is a strong immu-
Cathepsin S in Antigen Crosspresentation
161
Figure 7. Effects of TAP and Cat S on Gener-
ation of Primary CTL Responses against Influ-
enza Virus
(A–C) Detection of CTL cytotoxicity by 51Cr
release assay. The indicated BM chimeras
were depleted of CD4 T cells using GK1.5
ascites and then injected i.p. with 25 HAU (A)
or 100 HAU (B) influenza virus, or 20  106
pfu rVacESNP (C). Spleen cells were har-
vested and restimulated in vitro with 107 M
influenza NP peptide, and then 51Cr release
assays were performed. EL4 cells pulsed with
(solid) or without (open) NP peptide were
used as targets. In (B) and (C), the killing of
control EL4 targets (no peptide pulsing) was
less than 10% and is not included in the figure
for clarity. Results are expressed as % spe-
cific release. Each line is an individual mouse.
Two or three mice were used in each experi-
mental group.
(D and E) In vivo killing assay. The indicated
BM chimeras (three to five mice in each
group) were depleted of CD4 T and injected
i.p. with 200 HAU influenza virus. Seven days
after infection, B6.SJL (Ly5.1) spleen cells
(target cells) were pulsed with NP or PA pep-
tide or left unpulsed, and each target was
then labeled with a different concentration of
CFSE. The three target cells were mixed and
i.v. injected into infected or uninfected mice.
Ten hours later, blood was taken, and cells
were stained with APC-Ly5.1 antibody and
analyzed with flow cytometry. The percent of
in vivo killing is expressed as mean % kill-
ing  SD.
sol (Kovacsovics-Bankowski and Rock, 1995; Norbury dosomal proteases block TAP-independent presenta-
tion in intact cells. Moreover, isolated phagosomes con-et al., 1995). The antigens are then degraded by protea-
somes into oligopeptides that are transported by TAP tain proteases that can generate a class I-presented
peptide. Furthermore, this TAP-independent presenta-into the ER (Rock and Goldberg, 1999) or back into
phagosomes (Ackerman et al., 2003; Guermonprez et tion is inhibited in cells genetically lacking the endoso-
mal protease, Cat S. Similarly, isolated phagosomesal., 2003; Houde et al., 2003) where they bind to MHC
class I molecules. Other crosspresentation pathways lacking Cat S generate a class I-presented peptide very
poorly. Together, these data demonstrate that classhave also been described that do not require protea-
somes or newly synthesized class I molecules (Pfeifer et I-presented peptides are generated in phagosomes and
that Cat S plays a critical role in this process.al., 1993; Song and Harding, 1996), but their underlying
mechanisms were poorly understood. Often, these alter- These data indicate that, although the antigen initially
enters endocytic vesicles in both crosspresentationnate pathways do not require the TAP; however, in some
systems presentation was substantially lower without pathways, its subsequent fate is very different. In one
case it is hydrolyzed in the cytosol, while in the other itTAP (Song and Harding, 1996; Wick and Pfeifer, 1996).
It had been uncertain whether this partial TAP depen- is cleaved in endosomal vesicles. Although the path-
ways are different, both are active in cloned DC anddence was because TAP participates indirectly (e.g., to
allow export of class I molecules out of the ER to a macrophages (data not shown) as well as populations
of these primary APC, and therefore both pathways cancrosspresenting compartment), because these antigens
were being presented simultaneously by both TAP- operate simultaneously in the same cell. Having two
distinct pathways involved in generating peptides,dependent and -independent pathways, or because the
two pathways were not truly distinct. Here we show that potentially in different amounts and including new se-
quences, could serve to increase overall the total num-the two pathways are indeed distinct from one another
and use fundamentally different mechanisms that can be ber and diversity of peptides that are effectively pre-
sented and thereby broaden immune responses.distinguished by, among other things, TAP dependence.
The mechanism by which presented peptides were It is interesting that the loss of other cathepsins, in-
cluding B, L, and D (data not shown) had no effect ongenerated in the TAP-independent crosspresentation
pathways was unknown. We show that inhibitors of en- crosspresentation. It is possible that other proteases
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will be required for the presentation of other antigens Cat S-dependent vacuolar pathway is not only active
in vitro, but also in vivo. Moreover, we demonstrate that(Fonteneau et al., 2003). However, since Cat S was re-
quired for the presentation of three unrelated antigens, it contributes to the generation of immune responses
under physiological conditions. However, its contribu-OVA and influenza NP and PA, it may play an important
role generally in this pathway. It is not clear why Cat S, tion to the overall immune response to these antigens
appears to be less than the phagosome-to-cytosol path-but not other more abundant proteases, plays such a
critical role in vacuolar crosspresentation; however, way, at least with the antigens we have examined. Nev-
ertheless, the vacuolar pathway may play a more signifi-there are several possibilities that are not mutually ex-
clusive. cant role when APC are infected with viruses whose
immune evasion genes block the cytosolic pathway,Cat S is distributed throughout the entire endocytic
compartments and might be the predominant protease e.g., by inhibiting the TAP transporter. Moreover, during
viral infections, antiviral cytokines, including IFN
, arein the specific vesicles that generate the presented pep-
tides. Moreover, Cat S is different from other cathepsins produced. IFN
 can further induce Cat S expression
(Chapman et al., 1997) which in turn may augment vacu-because its activity is relatively pH insensitive (Shi et
al., 1992). We show that it generates SIINFEKL from olar antigen presentation. Hence, the TAP-independent,
Cat S-dependent pathway may play an even more im-OVA over a wide range of pH. This property may be
particularly important because class I molecules are un- portant role in the generation of immunity to certain
viral infections.stable and bind peptides inefficiently in acidic condi-
tions. Thus, it is possible that the vacuolar pathway Our data gives further insights into the generation
of immune responses to viral infections. Viral antigenoperates in vesicles with more neutral pH, such as early
endosomes (Ackerman et al., 2003), where Cat S will be presentation on MHC class I can occur when APC are
infected (direct priming) and/or when they acquire exog-the principal protease that is active. Interestingly, it was
reported (Lennon-Dumenil et al., 2002) that DC and mac- enous antigens (crosspriming). In situations where a vi-
rus only infects parenchymal cells (Sigal et al., 1999) orrophages phagosomes preferentially fuse with vesicles
enriched in Cat S, and perhaps antigen processing oc- blocks the function of infected DC (Shen et al., 2002),
then crosspriming plays a critical role in the generationcurs in these vacuoles before they acidify. It is also
possible that Cat S may be the only endosomal protease of immunity. However, in situations where the virus can
infect both parenchymal cells and DC, the contributionthat can make the proper peptides for MHC class I pre-
sentation. We show that Cat S makes the proper cleav- to immunity of crosspriming versus direct priming is
unknown. Influenza is a virus that can infect BM-derivedages in OVA to produce the epitope SIINFEKL in its
mature form. APC including DC. Our finding that the generation of CD8
T cell responses to influenza viral infection is reducedIt has been unclear why certain antigens are presented
exclusively by the cytosolic crosspresentation pathway in Cat S-deficient mice almost certainly indicates that
crosspriming contributes to these responses. Since awhile others use the vacuolar pathway. This may be
because not all epitopes can be generated by endoso- portion of the response is also likely to be generated
by the cytosolic crosspriming pathway, which is stillmal proteases or are destroyed. While it is likely that
this is a limiting factor in some situations, our data indi- operative in these mice, a substantial component of the
immune response may be stimulated by crosspriming.cate that this cannot be the sole reason for this phenom-
enon. Thus, in a situation where both pathways could We speculate that this is often likely to be the case with
cytopathic viruses because they may kill or inhibit thegenerate the exact same peptide (SIINFEKL) from the
same protein (OVA), the factor that influenced which function of infected APC in ways that interfere with their
ability to traffic to lymphoid organs and/or stimulatepathways were operative was whether the antigen was
associated with PLGA or iron oxide (or latex) particles. T cells. In any case, these data provide further evidence
that crosspriming is an important mechanism for theTherefore, the physical form of the antigen must influ-
ence its accessibility to the two pathways. It has pre- induction of viral immunity in vivo.
The physical form of antigen from cells that is cross-viously been shown that the chemical composition of
particles strongly influences where they localize in endo- presented in vivo has not been known. It is possible that
it is cellular protein (Serna et al., 2003; Shen and Rock,cytic compartments (Oh and Swanson, 1996). Similarly,
different pathogens have been shown to localize into 2004), free peptide (Kleindienst and Brocker, 2003), pep-
tide bound to heat shock proteins (HSP) (Srivastava,different, nonoverlapping endocytic compartments in
DC (Cervi et al., 2004). Thus, we speculate that some 2002), or even RNA (Freigang et al., 2003). Our finding
that Cat S is required for vacuolar crosspresentationparticles, such as PLGA, localize in compartments
where the vacuolar pathway is present (e.g., containing in vivo indicates that the form of antigen that is cross-
presented is one that requires proteolysis. This impliesCat S and higher pH) while others access different com-
partments where transfer to the cytosol occurs and Cat that under physiological conditions the crosspresented
antigen is acquired by APC as a protein or long peptide.S activity is lower.
The TAP-independent pathway of crosspresentation These findings lend independent support to other
emerging data that argue that the relevant form of anti-has been primarily demonstrated in cells in vitro (Pfeifer
et al., 1993; Reimann and Schirmbeck, 1999; Song and gen that is crosspresented in vitro (Serna et al., 2003)
and in vivo (Shen and Rock, 2004) is polypeptide inHarding, 1996; Wick and Pfeifer, 1996). In addition, there
are also a few reports that this pathway is operative nature and not a HSP-peptide complex.
In summary, we have shown that peptides presentedin vivo (Norbury et al., 2001; Ruedl et al., 2002; Sigal
and Rock, 2000); however, the mechanisms by which by the TAP-independent crosspresentation pathway are
generated by proteolysis in phagosomes. We have iden-this occurred were unknown. Our data show that the
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Digestion of OVA Using Recombinant Cat Stified Cat S as a key protease in this pathway and show
and Isolated Phagosomesthat it functions by generating the crosspresented pep-
OVA (500 g) was incubated with cathepsin S (10 g) or isolatedtide. We show that this pathway is truly separate from
phagosomes at 22C in 50 mM sodium acetate, 2.5 mM EDTA,
the TAP-dependent one and contributes to the presen- 2.5 mM TCEP (Tris [2-carboxyethyl] phosphine hydrochloride)
tation of cellular and viral antigens in vivo. (Pierce) (pH 4.5 to 6.5) at 22C for 16 hr. The cleavage of OVA was
confirmed by SDS-PAGE analysis of the reaction products (data not
shown). The digested materials were separated by Centricon 10
Experimental Procedures concentrators. In some experiments, the flowthrough (10 kDa) was
further separated by reverse phase HPLC using a C18 column. The
Mice fractions were washed, dried, and resuspended in PBS and used
C57BL/6, B6.129S2-Abcb2tm1Arp (C57BL/6 TAP/), and B6.129S6- to pulse fixed APC.
Iitm1Liz (C57BL/6 Ii/) mice were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). B6. SJL (Ly5.1) mice were purchased from
OT-I Adoptive Transfer and Proliferation Assay In Vivo
Taconic (Germantown, NY). Cat S (Shi et al., 1999), L (Nakagawa et
OT-I transgenic T cells were labeled with 1 M CFSE (Molecular
al., 1998), and B (Deussing et al., 1998) deficient mice were provided
Probes) at 37C for 30 min, and then 2.5–4  106 labeled cells were
by Dr. Hal Chapman (UCSF, San Francisco) and Dr. Hidde Ploegh
transferred i.v. to mice. One day after the transfer of T cells, mice
(Harvard Medical School) and were backcrossed to C57BL/6 back-
were immunized s.c. in the left flank with various dose of PLGA-
ground. OT-I T cell transgenic mice were made available by Dr.
OVA or DAP cells (H-2k) stably transfected with OVA in 100 l PBS.
William Heath at the Walter and Eliza Hall Institute and crossed with
At the indicated time points, draining and nondraining lymph nodes
B6.PL-Thy1a/Cy (Jackson Laboratory) to express the Thy1.1 marker.
and spleens were harvested. Cells were stained with PerCP-CD8
The preparation of BM chimeras was essentially as described (Sigal
and biotin-Thy1.1 followed by APC- streptavidin (all from BD Phar-
et al., 1999).
mingen) and analyzed by flow cytometry. The CFSE fluorescence
(FL1) in Thy1.1 and CD8 double-positive populations (transferred
OT-I T cells) was analyzed with FlowJo software.Cell Lines and Virus
RF33.70 (Rock et al., 1990b), DC2.4 (Shen et al., 1997), and DAP
Influenza and Recombinant Vaccinia CTL Assayscells (L cells) and its OVA-stable transfectants (Shen and Rock,
Either a low dose (25 HAU) or high dose (100 HAU) of influenza virus,2004) have been described. Recombinant vaccinia viruses, rVac-
or 20  106 pfu rVacESNP virus was injected i.p. into chimeric mice.ESOVA and rVacESNP (encoding SIINFEKL and ASNENMETM with
CD4 cells were depleted in all mice by three daily i.p. injections ofsignal sequences, respectively), were originally provided by Dr. J.
GK1.5 anti-CD4 ascites fluid. More than 95% of the CD4 T cellsYewdell (NIAID, Bethesda, MD). Influenza virus was A/PR/8/34
were depleted as shown by staining and flow cytometry of spleenstrain.
cells (data not shown). Fourteen days after influenza infection or
seven days after rVacESNP infection, spleen cells were restimulated
Antigen Microspheres with 1  107 M of influenza NP (ASNENMETM) peptide. On day 5
Amine-terminated iron BioMag beads (1 m in diameter) were pur- or 6 of the restimulation, a 51Cr release assay was carried out to
chased from Polysciences, Inc. (Warrington, PA). Covalent conjuga- determine the CTL cytotoxicity. EL4 cells were labeled and pulsed
tion of OVA to beads was performed according to the manufacturer’s with NP peptide and used as targets. In all experiments, the sponta-
protocol. OVA incorporated into microspheres of biodegradable co- neous release is less than 10% of the total release. All experiments
polymer polylactide polyglycolide (PLGA-OVA) was made and pro- were repeated at least three times with similar results.
vided by Corixa Cooperation (Seattle, WA).
In Vivo Killing Assay
The in vivo killing assay was carried out as described (Barber et al.,
Reagents 2003). Seven days after infection with 200 HAU of influenza virus
Chicken ovalbumin and leupeptin were purchased from Sigma (St. (i.p.), mice were i.v. injected with a mixture of three different target
Louis, MO). Proteasome inhibitor, clasto-lactacystin -lactone (Craiu cells (7.5  106 each). Target cells were B6.SJL strain (expressing
et al., 1997), was kindly provided by Dr. J. Adams (ProScript, Cam- Ly5.1 congenic marker) spleen cells pulsed with influenza NP or PA
bridge, MA). Recombinant human Cat S was kindly provided by Dr. peptides or unpulsed, and then labeled with 1.0, 0.25, or 0.06 M
M. Brown (Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT). CFSE, respectively. Ten hours after the injection of target cells,
OVA SIINFEKL, influenza NP ASNENMETM, and PA SSLENFRAYV blood was taken and RBC lysed and stained with APC-conjugated
peptides were obtained commercially or from Tom Vedvick at Corixa anti-Ly5.1 antibody. The elimination of Ly5.1 and CFSE-positive
and Dr. Ray Welsh at UMass Medical School. target cells was measured by flow cytometry and analyzed using
FlowJo software. The percent killing was calculated as follows:
100  {[(% peptide pulsed in infected/% unpulsed in infected)/(%Preparation of BM-Derived DC and Macrophages
peptide pulsed in uninfected/% unpulsed in uninfected)]  100}.and Isolation of Phagosomes
BM cells were cultured with 10 ng/ml GM-CSF and 5 ng/ml IL-4 to
Acknowledgmentsgenerate DC. To generate BM macrophages, 10% DAP cell superna-
tant which contains M-CSF was added to cultures. Both DC and
We would like to thank Dr. S. Raychaudhuri and M. Johnson (Corixamacrophages were used after 6 or 7 days of culture. The isolation
Corporation, Seattle) for providing PLGA-OVA microspheres, Dr.of phagosomes was performed essentially as described (Desjardins
Hidde Ploegh (Harvard Medical School) and Dr. Harold Chapmanet al., 1994).
(UCSF) for providing cathepsin knockout mice, Dr. Jonathan Yewdell
(NIH) for rVacESOVA and rVacESNP, and Drs. Dale Greiner and
Raymond Welsh (University of Massachusetts Medical School) forAntigen Presentation Assays
Antigen presentation assays with T cell hybrids were performed providing anti-CD4 antibody. We thank Dr. M. Brown (Boehringer
Ingelheim Pharmaceuticals) for providing recombinant Cat S. Weessentially as described before (Shen et al., 1997). In addition to
T cell hybridomas, antigen presentation assays were also performed also thank Dr. Ian York at (UMass Medical School) for helpful discus-
sions and Dr. Hidde Ploegh (Harvard Medical School) for criticalusing OT-I T cell. OVA digest (10 K flowthrough) or HPLC peptide
fractions were assayed by incubating them with fixed DC2.4 cells reading of the manuscript. Dr. Joseph Maciaszek has kindly helped
with the construction of chimeric mice. L.S. was supported by ain serum-free media for 2 hr at 37C. The cells were then washed
and incubated with OT-1 T cells. The proliferation of OT-I cell was fellowship from the Canadian Institutes of Health Research (CIHR).
M.B. was supported by a fellowship from the Cancer Researchassayed by measuring the incorporation of [3H]thymidine into
DNA (cpm). Institute. This work was supported by grants to K.L.R. from the NIH.
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